V-BID X: Expanding Coverage of Essential Clinical Care Without Increasing Premiums or Deductibles

A. Mark Fendrick, MD
University of Michigan Center for Value-Based Insurance Design

www.vbidcenter.org





Hail to the Frontline

So many selfless people are doing truly wonderful things to successfully defeat this pandemic. Thank you.




Health Care Costs Are a Top Issue For Purchasers and Policymakers: Solutions must protect consumers, reward providers and preserve innovation


- Irrespective of remarkable clinical advances, cutting health care spending is the main focus of reform discussions
- Everyone (almost) agrees there is enough money in the US health care system; we just spend it on the wrong services
- Policy deliberations focus primarily on alternative payment models, but moving to value-based system also requires a change in how we engage consumers to seek care



Then Came Coronavirus...








LOW-VALUE CARE

A silver lining to COVID-19: Fewer low-value elective procedures






Patient Rushed Into Unnecessary Surgery To Save Cash-Strapped Hospital bit.ly/314r3zN



Crisis Into Opportunity: Can COVID-19 Help Set a Path to Improved Health Care Efficiency?




Crisis Into Opportunity: Can COVID-19 Help Set a Path to Improved Health Care Efficiency?

- Build on existing alternative payment models that base reimbursement on patient-centered outcomes. increase reimbursement for high-value services and reduce or cease payment for known low-value care
- Leverage the widespread adoption of telemedicine and electronic health records (EHRs) to make it easier to order high-value care and discourage the use of low-value
- Align patient cost-sharing with the value of the underlying services;
 reduce out of pocket cost on high value services and increase patient cost on low value care




Americans Do Not Care About Health Care Costs; They Care About What It Costs Them




NEARLY THREE IN FOUR AMERICANS SAY THEIR INCOMES HAVE ALREADY TAKEN A HIT FROM THE PANDEMIC



Health Plan Deductibles have grown more than ten times faster than inflation over the last decade





Concerns Regarding Out of Pocket Costs: Americans Cannot Afford Essential Care

- About half of the public have skipped or postponed care because of the coronavirus outbreak
- 68% of adults report out-of-pocket costs would be very or somewhat important in their decision to get care if they had coronavirus symptoms
- Insured patients are responsible for over \$1,000 for a COVID-19 hospitalization
- 40% of Americans do not have \$400 for an expected expense



An Alternative to 'Blunt' Cost-Sharing Approaches: Clinically Nuanced' Cost-Sharing

A "smarter" cost-sharing approach that encourages consumers to use more high value services and providers, but discourages the use of low value ones




Alternative to "Blunt" Consumer Cost Sharing: Value-Based Insurance Design (V-BID)

- **Sets consumer cost**sharing on clinical benefit – not price
- Little or no out-ofpocket cost for high value care; high cost share for low value care
- Successfully implemented by hundreds of public and private payers



Health Plans That Nudge Patients to Do the Right Thing















ACA Sec 2713: Selected Preventive Services be Provided without Cost-Sharing

- Receiving an A or B rating from the United States Preventive Services Taskforce (USPSTF)
- Immunizations recommended by the Advisory Committee on Immunization Practices (ACIP)
- Preventive care and screenings supported by the Health Resources and Services Administration (HRSA)

Over 137 million Americans have received expanded coverage of preventive services

Medicare Advantage V-BID Model Test: Expanded Opportunities

Permissible interventions:

Reduced cost-sharing for

- high-value services
- high-value providers
- enrollees participating in disease management or related programs
- additional supplemental benefits (non-health related)

Wellness and Health Care Planning

Advanced care planning

Incentivize better health behaviors

Rewards and Incentives

\$600 annual limit

Increase participation

Available for Part D

Targeting Socioeconomic Status

Low-income subsidy

Improve quality, decrease costs

Telehealth

Service delivery innovations

Augment existing provider networks



HSA-HDHP Reform





IRS Rules Prohibit Coverage of Chronic Disease Care Until HSA-HDHP Deductible is Met

PREVENTIVE CARE COVERED

Dollar one

CHRONIC DISEASE CARE

NOT covered until deductible is met







U.S. DEPARTMENT OF THE TREASURY

PRESS RELEASES

Treasury Expands Health Savings Account Benefits for Individuals Suffering from Chronic Conditions

List of services and drugs for certain chronic conditions that will be classified as preventive care under Notice 2019-45

| Preventive Care for Specified Conditions | For Individuals Diagnosed with |
|---|---|
| Angiotensin Converting Enzyme (ACE) inhibitors | Congestive heart failure, diabetes, and/or |
| | coronary artery disease |
| Anti-resorptive therapy | Osteoporosis and/or osteopenia |
| Beta-blockers | Congestive heart failure and/or coronary artery |
| | disease |
| Blood pressure monitor | Hypertension |
| Inhaled corticosteroids | Asthma |
| Insulin and other glucose lowering agents | Diabetes |
| Retinopathy screening | Diabetes |
| Peak flow meter | Asthma |
| Glucometer | Diabetes |
| Hemoglobin A1c testing | Diabetes |
| International Normalized Ratio (INR) testing | Liver disease and/or bleeding disorders |
| Low-density Lipoprotein (LDL) testing | Heart disease |
| Selective Serotonin Reuptake Inhibitors (SSRIs) | Depression |
| Statins | Heart disease and/or diabetes |

List of services and drugs for certain chronic conditions that will be classified as preventive care under Notice 2019-45

| Preventive Care for Specified Conditions | For Individuals Diagnosed with |
|---|--|
| Angiotensin Converting Enzyme (ACE) inhibitors | Congestive heart failure, diabetes, and/or |

"Under this policy, no American should ever have to pay full list price for essential drugs like insulin ever again."

| The modern that testing | Diabetes |
|---|---|
| International Normalized Ratio (INR) testing | Liver disease and/or bleeding disorders |
| Low-density Lipoprotein (LDL) testing | Heart disease |
| Selective Serotonin Reuptake Inhibitors (SSRIs) | Depression |
| Statins | Heart disease and/or diabetes |

Paying for more generous coverage of high value care

Raise Premiums



Paying for more generous coverage of high value care

- Raise Premiums
- Increase Deductibles, Copayments and Coinsurance a tax on the sick



Paying for more generous coverage of high value care

- Raise Premiums
- Increase Deductibles, Copayments and Coinsurance
- Reduce Spending on Low Value Care



We can pay for more generous coverage of high-value care through reduced utilization of low-value care

\$345 BILLION

is spent annually on low-value or harmful care in the United States.

Examples include:



Vitamin D screening tests



Diagnostic tests before low-risk surgery



PSA screening for men 70 and older



Branded drugs when identical generics are available



Low-back pain imaging within 6 weeks of onset

V-BID X: Better Coverage, Same Premiums and Deductibles





V-BID X: Expanding Coverage of Essential Clinical Care Without Increasing Premiums or Deductibles

Clinically driven plan designs, like *V-BID X*, reduce spending on low-value care



...creating headroom to reallocate spending to high-value services without increasing premiums or deductibles

V-BID X: Guiding Principles

- Make concrete recommendations
- Anticipate and address barriers
- Payers must be able to use template to design a V-BID product
- The best must not be the enemy of the good
- Output would be publically available

Identification of services:

- 1. Favor services with the strongest evidence-base
- 2. Favor services that are more responsive to cost-sharing
- 3. Favor services with a high likelihood to be high- or low-value, independent of the clinical context
- 4. Focus on areas with most need for improvement
- 5. Consider equity, adverse selection, impact on special populations, and the risk pool

V-BID X: Project Members











- Research supported by Arnold Ventures
- Oliver Wyman provided actuarial estimates

High-Value Services and Drugs with Highly Reduced or Eliminated Cost-Sharing

| Glucometers and testing strips | Anti-thrombotic/anticoagulants |
|--|--------------------------------|
| LDL testing (hyperlipidemia) | Anti-depressants |
| Hemoglobin A1C testing (diabetes) | Statins |
| Cardiac rehabilitation | Antipsychotics |
| INR testing (hypercoagulability) | ACE inhibitors and ARBs |
| Pulmonary rehabilitation | Beta blockers |
| Peak flow meters (asthma) | Buprenorphine-naloxone |
| Blood pressure monitors (hypertension) | Anti-resorptive therapy |
| Glucose lowering agents | Tobacco cessation treatments |
| Rheumatoid arthritis medications | Naloxone |
| Inhaled Corticosteroids | Thyroid-related |
| Antiretrovirals | |

High-Value Branded Drug Classes with Reduced Cost-Sharing

Pre-exposure prophylaxis for HIV

Hepatitis C directing-acting combination

Anti-TNF

Low-Value Services with No Coverage

Spinal fusions

Vertebroplasty and kyphoplasty

Vitamin D testing

Proton beam therapy for prostate cancer

Commonly Used Services with Limited Value and Increased Cost-Sharing

| Outpatient specialist services | X-rays and other diagnostic imaging |
|--------------------------------|-------------------------------------|
| Outpatient labs | Outpatient surgical procedures |
| High-cost imaging | Non-preferred branded drugs |

V-BID X: Plan Flexibility

The list of services and service categories used in this first iteration of V-BID X represents just one version of what such a plan design could look like.

Payers have significant flexibility regarding how to design a version of V-BID X. Key parameters include:

- Selection of high-value services for reduced cost-sharing
- Level of cost-sharing reduction for high-value services
- Selection of low-value services for increased cost sharing
- Level of cost-sharing increase for low-value services
- Determination of the actuarial value of the plan

HHS 2021 Payment Rule Strongly Endorses V-BID X

6. Promoting Value-Based Insurance Design

Borrowing from work provided by the Center for Value-based Insurance Design at the University of Michigan ¹⁵⁶ (the Center), Table 5 lists high value services and drugs that an issuer may want to consider offering with lower or zero cost sharing. Table 5 also includes a list of low value services that issuers should consider setting at higher consumer cost sharing. High value services are those

V-BID X: Key Takeaways

 Cost neutral V-BID designs are feasible. Coverage can be enhanced for targeted high-value services, without raising premiums and deductibles

 There are a large number of plausible combinations of services or cost-sharing changes that could fit different needs and goals, depending on the carrier and market

V-BID X: More Generous Coverage of Essential Clinical Care Without Increasing Premiums or Deductibles

- Expand pre-deductible coverage/reduce cost sharing on high value clinical services
- Identify, measure and reduce low value care to pay for more generous coverage of high value care
- Implement clinically-driven payment models and plan designs that increase use of high value services and deter the use of low value ones



